These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 25579296)

  • 1. Safe duration of postoperative monitoring for malignant hyperthermia patients administered non-triggering anaesthesia: an update.
    Barnes C; Stowell KM; Bulger T; Langton E; Pollock N
    Anaesth Intensive Care; 2015 Jan; 43(1):98-104. PubMed ID: 25579296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safe duration of postoperative monitoring for malignant hyperthermia susceptible patients.
    Pollock N; Langtont E; Stowell K; Simpson C; McDonnell N
    Anaesth Intensive Care; 2004 Aug; 32(4):502-9. PubMed ID: 15675210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test.
    Bendixen D; Skovgaard LT; Ording H
    Acta Anaesthesiol Scand; 1997 Apr; 41(4):480-4. PubMed ID: 9150775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States.
    Larach MG; Brandom BW; Allen GC; Gronert GA; Lehman EB
    Anesth Analg; 2014 Dec; 119(6):1359-66. PubMed ID: 25268394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of exposure of malignant hyperthermia non-susceptible patients and their relatives to anaesthetic triggering agents.
    Pollock N; Langton EE; Stowell KM; Bulger TF
    Anaesth Intensive Care; 2011 Sep; 39(5):887-94. PubMed ID: 21970134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy.
    Carr AS; Lerman J; Cunliffe M; McLeod ME; Britt BA
    Can J Anaesth; 1995 Apr; 42(4):281-6. PubMed ID: 7788824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant hyperthermia susceptibility: anaesthetic implications and risk stratification.
    Ben Abraham R; Cahana A; Krivosic-Horber RM; Perel A
    QJM; 1997 Jan; 90(1):13-8. PubMed ID: 9093584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant hyperthermia and day stay surgery.
    Pollock N; Langton E; McDonnell N; Tiemessen J; Stowell K
    Anaesth Intensive Care; 2006 Feb; 34(1):40-5. PubMed ID: 16494148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of malignant hyperthermia in patients administered triggering agents before malignant hyperthermia susceptibility identified: missed opportunities prior to diagnosis.
    Chan TY; Bulger TF; Stowell KM; Gillies RL; Langton EE; Street NE; Pollock NA
    Anaesth Intensive Care; 2017 Nov; 45(6):707-713. PubMed ID: 29137581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Administration of anaesthetic triggering agents to patients tested malignant hyperthermia normal and their relatives in New Zealand: an update.
    Frei D; Stowell KM; Langton EE; McRedmond L; Pollock NA; Bulger TF
    Anaesth Intensive Care; 2017 Sep; 45(5):611-618. PubMed ID: 28911291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized.
    Halsall PJ; Cain PA; Ellis FR
    Br J Anaesth; 1979 Oct; 51(10):949-54. PubMed ID: 518796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. McArdle's disease and anaesthesia: case reports. Review of potential problems and association with malignant hyperthermia.
    Bollig G; Mohr S; Raeder J
    Acta Anaesthesiol Scand; 2005 Sep; 49(8):1077-83. PubMed ID: 16095447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of 119 anaesthetics received after investigation for susceptibility to malignant hyperthermia.
    Ording H; Hedengran AM; Skovgaard LT
    Acta Anaesthesiol Scand; 1991 Nov; 35(8):711-6. PubMed ID: 1763590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current understanding of malignant hyperthermia: genesis, prevention, and treatment.
    Katz DN
    CRNA; 1992 May; 3(2):54-63. PubMed ID: 1483145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Malignant hyperthermia--diagnostics, treatment and anaesthetic management].
    Schuster F; Müller-Reible CR
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2009 Nov; 44(11-12):758-63; quiz 764. PubMed ID: 19918708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anesthesia for patients with a history of malignant hyperthermia.
    Wappler F
    Curr Opin Anaesthesiol; 2010 Jun; 23(3):417-22. PubMed ID: 20173632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuromuscular conditions associated with malignant hyperthermia in paediatric patients: A 25-year retrospective study.
    Bamaga AK; Riazi S; Amburgey K; Ong S; Halliday W; Diamandis P; Guerguerian AM; Dowling JJ; Yoon G
    Neuromuscul Disord; 2016 Mar; 26(3):201-6. PubMed ID: 26951757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006.
    Larach MG; Gronert GA; Allen GC; Brandom BW; Lehman EB
    Anesth Analg; 2010 Feb; 110(2):498-507. PubMed ID: 20081135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative malignant hyperthermia episodes in patients who received "safe" anaesthetics.
    Grinberg R; Edelist G; Gordon A
    Can Anaesth Soc J; 1983 May; 30(3 Pt 1):273-6. PubMed ID: 6336548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative malignant hyperthermia: an analysis of cases from the North American Malignant Hyperthermia Registry.
    Litman RS; Flood CD; Kaplan RF; Kim YL; Tobin JR
    Anesthesiology; 2008 Nov; 109(5):825-9. PubMed ID: 18946294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.